Kenneth L Waggoner

CEO

Kenneth L. Waggoner served as the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech, Inc. between 2013 and 2022. During that time, he was also the Chairman of the Board. In his multifaceted roles, Mr. Waggoner was responsible for the success of PharmaCyte’s clinical development programs for pancreatic cancer, diabetes, and malignant ascites. In that role, he secured Orphan Drug designation for the company’s pancreatic cancer treatment and was responsible for working with the US Food and Drug Administration (FDA) to submit an Investigational New Drug application (IND) to begin a late-phase clinical trial in pancreatic cancer. Mr. Waggoner also created an International Diabetes Consortium to fast-track the company’s diabetes development program. He was responsible for the accomplishment of PharmaCyte’s mission and vision and the accountability of PharmaCyte’s constituents. He also led the Board of Directors. Mr. Waggoner provided general oversight of all PharmaCyte’s activities, managed the day-to-day operations, and assured a smoothly functioning, efficient organization. Mr. Waggoner also assured program quality and organizational stability through development and implementation of standards and controls, systems and procedures and regular evaluation. Mr. Waggoner oversaw the fiscal activities of PharmaCyte, including budgeting, reporting, and auditing. As General Counsel, Mr. Waggoner assured the timely filing of all legal and regulatory documents and monitored compliance with relevant laws and regulations. In 2013, Mr. Waggoner orchestrated the transition of PharmaCyte from a nutraceutical company to a worldwide, fully integrated biotechnology company. Through his leadership, PharmaCyte was uplisted to Nasdaq having previously traded on the OTCQB for many years. Concurrently with the Nasdaq listing, Mr. Waggoner raised approximately $90 million to support PharmaCyte’s worldwide operations and research and development efforts. Mr. Waggoner has 45 years of experience in management, business, operations, and law. Mr. Waggoner started his career as an attorney in private practice. From 1986 to 2003, he was senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to technology clients, such as Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others. He was also the Managing Partner of Brobeck's Los Angeles office. In addition, Mr. Waggoner served as a member of Brobeck’s Executive Committee for numerous years managing Brobeck's worldwide operations. While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck's worldwide Environmental Law Group. From 2003 to 2005, Mr. Waggoner served as the Vice President and General Counsel of Chevron’s global downstream operations. There, he was responsible for the overall management of legal services to Chevron’s North American, Latin American, European, and Asian products companies. While at Chevron, he also led the successful restructuring of Chevron’s global Legal Department following Chevron’s acquisition of Texaco. Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies as well as working with Fortune 500 companies, like Chevron. Mr. Waggoner received his Juris Doctorate with honors in 1973 from Loyola University School of Law in Los Angeles.

WILLIAM HISEY

CFO

Mr. Hisey is a veteran business executive, having held senior positions in business operations and finance, including private equity and corporate finance. His experiences run the spectrum from initial start-ups to Fortune 100 Companies. Mr. Hisey began his career at Ernst & Young as a financial auditor, before moving on to multiple financial roles at Pitney Bowes for the next decade. After several years as VP Business Development at IVAX Pharmaceuticals, he became CFO of the boutique venture capital firm Snowmark Capital. Mr. Hisey then transitioned to the entrepreneurial side of business by founding RxStrategies, a 340b pharmaceutical services startup, focusing on developing the business model, raising capital, and directing the ramp up of company infrastructure and front of the house activities. Subsequently, he served various roles at Sentry Data Systems, including CFO and VP-Business Development. Mr. Hisey has spent the last 13 years consulting with new business startups and providing fractional CFO services, primarily through Wired4Health. From 2011 to present, Mr. Hisey has provided CFO and private equity services to a variety of companies, while also serving as the CFO for Wied4Health. These activities include financial structuring, business modeling, strategic planning, capital raises and due diligence/process improvement projects. From January 2005 to August 2010, Mr. Hisey held various roles with Sentry Data Systems, a healthcare solutions technology company, a PBM focused company. These roles included CFO and VP – Business Development. During his tenure, the company grew from 15 employees to 100+ employees with revenues growing dramatically from less than $1mm to $100mm+. He was instrumental in securing company recapitalization with PE firm and the ultimate sale to Craneware Corporation.